- Conditions
- Healthy
- Interventions
- Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 9,285
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Subjects
- Interventions
- Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- BLZ-100
- Drug
- Lead sponsor
- Blaze Bioscience Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lakewood, Colorado
- Conditions
- Her2 Amplified Solid Tumors, Metastatic Breast Cancer
- Interventions
- MM-111
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Neuropathic Pain
- Interventions
- LY4286533, placebo
- Drug
- Lead sponsor
- 4E Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Fasinumab AI, Fasinumab PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- HM-002-1005
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- HIV Infection
- Interventions
- Griffithsin Gel, Placebo Gel
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Friedreich Ataxia
- Interventions
- CTI-1601, Placebo
- Biological
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
- Interventions
- Brentuximab Vedotin, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
- Conditions
- Healthy
- Interventions
- Rosuvastatin, Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
- Interventions
- ARR-002
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Boston, Massachusetts • Nashville, Tennessee + 3 more
- Conditions
- Post-transplant Lymphoproliferative Disorder
- Interventions
- Loncastuximab tesirine, Rituximab or rituximab biosimilar
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Relapsed Multiple Myeloma, End-stage Renal Disease
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Detroit, Michigan • Lake Success, New York • Canton, Ohio + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled AR-501, Inhaled Placebo
- Drug
- Lead sponsor
- Aridis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
- Interventions
- 64Cu-LNTH-1363S
- Combination Product
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Orange, California • Stanford, California + 2 more
- Conditions
- COVID-19
- Interventions
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo
- Combination Product · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pelitinib, temsirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple
- Interventions
- Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 73 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Epithelial Cancer
- Interventions
- SPL-108
- Drug
- Lead sponsor
- Splash Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Interventions
- Angiogram, Biospecimen Collection, Computed Tomography, Radioembolization, Single Photon Emission Computed Tomography, Survey Administration, Yttrium Y 90 Glass Microspheres
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Aurora, Colorado
- Conditions
- Healthy Volunteers
- Interventions
- S-337395, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida